Bone metastasis market grows with new therapies but faces high costs and limited FDA approvals

The bone metastasis in solid tumors market is expanding due to rising cases of cancers like breast, prostate, lung, and renal cell carcinoma that spread to bones. Advances in targeted therapies and immunotherapy, including drugs like denosumab and bisphosphonates, improve patient outcomes but remain costly and limited in FDA-approved options. Emerging trends include combination therapies and personalized medicine using genetic profiling to enhance treatment effectiveness. Companies are also exploring innovative treatments such as gene therapies and oncolytic viruses to address bone metastasis challenges and improve patient care.